FIELD: biotechnology.
SUBSTANCE: presented are a nucleic acid molecule encoding a synthetic consensus Survivin antigen (variants), a synthetic consensus Survivin antigen (variants), an expression vector, an immunogenic composition (variants), a vaccine for treating or preventing Survivin-expressing cancer, a method for treating a subject with a Survivin-expressing cancer cell, and a method for vaccinating a subject against a Survivin-expressing cancer cell.
EFFECT: production of safe and effective vaccines and methods for application thereof for preventing and/or treating cancer and reducing the mortality in subjects suffering from cancer.
22 cl, 14 tbl, 32 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-CANCER VACCINES TARGETED WITH SURVIVIN AND THEIR APPLICATION | 2018 |
|
RU2751253C1 |
| ANTICANCER VACCINES TARGETING BORIS AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2759681C1 |
| BORIS-TARGETED ANTI-CANCER VACCINES AND METHODS FOR APPLICATION THEREOF | 2018 |
|
RU2799786C2 |
| ANTI-CANCER VACCINES AIMED AT LEMD1 AND THEIR USE | 2018 |
|
RU2760984C1 |
| MUC16-TARGETING ANTICANCER VACCINES AND APPLICATION THEREOF | 2018 |
|
RU2777918C2 |
| ANTI-CANCER VACCINES TARGETING MUC16 AND THEIR USE | 2018 |
|
RU2750689C1 |
| ANTI-CANCER VACCINES TARGETING PRAME AND THEIR APPLICATIONS | 2018 |
|
RU2748903C1 |
| MESOTHELINE-TARGETED CANCER VACCINES AND THEIR APPLICATION | 2018 |
|
RU2751252C1 |
| MESOTHELIN-TARGETED CANCER VACCINES AND THEIR APPLICATIONS | 2018 |
|
RU2830879C2 |
| DNA-VACCINE AGAINST TUMORAL GROWTH AND WAYS OF THEIR APPLICATION | 2004 |
|
RU2343195C2 |
